2016
DOI: 10.1080/15384101.2016.1249545
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Biguanides, including metformin (widely used in diabetes treatment) and phenformin, are AMP-activated protein kinase (AMPK) activators and potential drugs for cancer treatment. A more in-depth understanding of how cancer cells adapt to biguanide treatment may provide important therapeutic implications to achieve more effective and rational cancer therapies. NBR2 is a glucose starvation-induced long non-coding RNA (lncRNA) that interacts with AMPK and regulates AMPK activity upon glucose starvation. Here we sho… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
55
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 63 publications
(56 citation statements)
references
References 54 publications
1
55
0
Order By: Relevance
“…The data showed that miR‐19a negatively regulated the expression of both NBR2 and AMPK/PPARα. Except being involved in cancer [Liu and Gan, ; Xiao et al, ], NBR2 was regarded as a stress‐related molecule that has been reported by Liu et al []. Our data further confirms the key role of NBR2 in cell death‐induced cell stress.…”
Section: Discussionsupporting
confidence: 88%
“…The data showed that miR‐19a negatively regulated the expression of both NBR2 and AMPK/PPARα. Except being involved in cancer [Liu and Gan, ; Xiao et al, ], NBR2 was regarded as a stress‐related molecule that has been reported by Liu et al []. Our data further confirms the key role of NBR2 in cell death‐induced cell stress.…”
Section: Discussionsupporting
confidence: 88%
“…Moreover, NBR2 deficiency promotes unchecked progression of the cell cycle under energy stress and enhances tumor development in vivo . In addition, another study indicated that NBR2 may serve as an adaptive response in breast cancer and kidney cancer cells to survive in response to phenformin treatment . However, the role of NBR2 in the development of osteosarcoma remains unknown.…”
Section: Discussionmentioning
confidence: 99%
“…If so, hypoxia-induced epigenetic silencing of the BRCA1 promoter may cause loss of both BRCA1 and NBR2 expression and then promote tumorigenesis via two distinct mechanisms, i.e., genetic instability from loss of BRCA1 and reduced AMPK activation from loss of NBR2. One potential advantage from loss of NBR2 expression in cancer is that decreased NBR2 levels sensitize tumor cells to biguanides [42], which are used in cancer treatment because they inhibit mitochondrial respiratory function [43].…”
Section: Discussionmentioning
confidence: 99%